Cybin Inc.

NYSEAM:CYBN Stock Report

Market Cap: US$212.8m

Cybin Valuation

Is CYBN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CYBN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CYBN ($10.71) is trading below our estimate of fair value ($948.99)

Significantly Below Fair Value: CYBN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CYBN?

Key metric: As CYBN is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CYBN. This is calculated by dividing CYBN's market cap by their current book value.
What is CYBN's PB Ratio?
PB Ratio1.2x
BookCA$255.02m
Market CapCA$299.36m

Price to Book Ratio vs Peers

How does CYBN's PB Ratio compare to its peers?

The above table shows the PB ratio for CYBN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average5.7x
TRVI Trevi Therapeutics
3.8x12.1%US$224.4m
BSEM BioStem Technologies
9.8x33.8%US$223.5m
NKTR Nektar Therapeutics
4x-6.1%US$201.1m
MDWD MediWound
5.3x60.2%US$187.0m
CYBN Cybin
1.2x48.8%US$212.8m

Price-To-Book vs Peers: CYBN is good value based on its Price-To-Book Ratio (1.2x) compared to the peer average (5.7x).

Price to Book Ratio vs Industry

How does CYBN's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

23 CompaniesPrice / BookEstimated GrowthMarket Cap
SHWZ Medicine Man Technologies
0.1xn/aUS$8.02m
TNFA TNF Pharmaceuticals
0.2xn/aUS$3.86m
UPC Universe Pharmaceuticals
0.1xn/aUS$2.93m
CYTO Altamira Therapeutics
0.2x-5.9%US$1.45m
CYBN 1.2xIndustry Avg. 1.7xNo. of Companies29PB01.22.43.64.86+
23 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: CYBN is good value based on its Price-To-Book Ratio (1.2x) compared to the US Pharmaceuticals industry average (1.7x).

Price to Book Ratio vs Fair Ratio

What is CYBN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CYBN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CYBN's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CYBN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$10.71
US$104.42
+874.9%
57.1%US$191.14US$25.15n/a4
Nov ’25US$9.99
US$153.69
+1,438.4%
34.4%US$224.33US$92.81n/a4
Oct ’25US$8.84
US$158.40
+1,691.9%
34.7%US$231.79US$95.90n/a4
Sep ’25US$9.69
US$163.30
+1,585.3%
30.5%US$231.72US$115.68n/a4
Aug ’25US$10.51
US$161.87
+1,440.0%
27.2%US$226.16US$113.08n/a5
Jul ’25US$10.07
US$162.67
+1,515.3%
27.1%US$228.04US$114.02n/a5
Jun ’25US$13.30
US$169.93
+1,177.7%
21.9%US$225.57US$114.56n/a5
May ’25US$13.30
US$184.61
+1,288.0%
15.2%US$227.02US$151.35n/a4
Apr ’25US$16.12
US$184.61
+1,045.5%
15.2%US$227.02US$151.35n/a4
Mar ’25US$12.73
US$185.57
+1,357.8%
15.2%US$228.41US$152.18n/a4
Feb ’25US$13.83
US$196.39
+1,319.8%
10.8%US$229.72US$170.90n/a4
Jan ’25US$15.58
US$195.83
+1,156.9%
10.5%US$228.06US$171.05n/a4
Dec ’24US$17.48
US$195.83
+1,020.3%
10.5%US$228.06US$171.05n/a4
Nov ’24US$21.70
US$212.49
+879.3%
47.5%US$380.59US$111.96US$9.994
Oct ’24US$20.19
US$210.34
+941.6%
49.0%US$382.77US$115.14US$8.844
Sep ’24US$11.82
US$208.33
+1,662.8%
49.2%US$379.46US$112.95US$9.694
Aug ’24US$12.05
US$202.24
+1,578.9%
49.2%US$382.08US$114.09US$10.515
Jul ’24US$14.36
US$210.10
+1,362.7%
46.5%US$379.85US$113.97US$10.075
Jun ’24US$10.11
US$218.45
+2,061.2%
46.8%US$385.01US$113.96US$13.305
May ’24US$13.11
US$215.91
+1,547.4%
46.8%US$380.45US$112.72US$13.305
Apr ’24US$14.63
US$215.91
+1,375.8%
46.8%US$380.45US$112.72US$16.125
Mar ’24US$18.05
US$222.10
+1,130.4%
41.3%US$374.77US$114.08US$12.735
Feb ’24US$16.56
US$226.03
+1,264.6%
39.0%US$391.57US$117.02US$13.836
Jan ’24US$11.29
US$219.24
+1,841.9%
39.0%US$379.98US$113.55US$15.586
Dec ’23US$13.87
US$265.49
+1,814.6%
31.5%US$380.83US$152.31US$17.486
Nov ’23US$17.68
US$290.93
+1,545.8%
29.7%US$372.76US$151.31US$21.706

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.9b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.59

7D

-1.3%

1Y

69.3%

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$31.19

7D

4.8%

1Y

22.3%

IQVIA Holdings

US$37.0b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.23

7D

5.2%

1Y

-4.6%